Your session is about to expire
← Back to Search
Risk Score
Risk Reduction Intervention for Iatrogenic Disease (AGING Trial)
N/A
Recruiting
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Baseline medication risk score of 20 or more
Hospital admission for at least 48 hours
Must not have
Discharge to hospice
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of intervention
Awards & highlights
Summary
This trial will test whether the MedWise Risk Score can help identify which patients are at high risk for readmission and target them for interventions.
Who is the study for?
This trial is for older adults who were in the hospital for at least 2 days, have a high medication risk score (20+), and are taking 5 or more medications upon leaving the hospital. It's not for those who left the hospital against advice, passed away during their stay, live far from the facility, or went to hospice care.
What is being tested?
The study tests if using MedWise Risk Score™ to guide treatment can lower this score and reduce chances of being readmitted within 30 days after discharge. High-risk patients will receive special attention to adjust their meds.
What are the potential side effects?
Since this intervention involves adjusting existing medications rather than testing new ones, side effects will vary based on changes made to each patient's medication regimen.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My medication risk score is 20 or higher.
Select...
I have been admitted to the hospital for at least 48 hours.
Select...
I was prescribed 5 or more medications when I left the hospital.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am being discharged to hospice care.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days after hospital discharge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days after hospital discharge
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of individuals with an emergency department visit or hospital readmission
Secondary outcome measures
Difference in score between patients aged older and younger than 65 years
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Discharge medication regimen instructions will be provided upon discharge after being assessed using the MWRS, optimized, and assessed by the prescriber.
Group II: Standard of CareActive Control1 Intervention
Discharge medication regimen instructions will be provided upon discharge after being assessed by the prescriber.
Find a Location
Who is running the clinical trial?
Rutgers, The State University of New JerseyLead Sponsor
435 Previous Clinical Trials
64,223 Total Patients Enrolled
1 Trials studying Iatrogenic Disease
80 Patients Enrolled for Iatrogenic Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My medication risk score is 20 or higher.I have been admitted to the hospital for at least 48 hours.I am being discharged to hospice care.I was prescribed 5 or more medications when I left the hospital.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Standard of Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger